Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
2,108
archived clinical trials in
Lupus

Atorvastatin to Prevent Avascular Necrosis of Bone in Steroid Treated Exacerbated Systemic Lupus Erythematosus
AVN Prevention With Lipitor in Lupus Erythematosus APLLE Trial
Status: Enrolling
Updated:  12/31/1969
New York University, The Hospital for Joint Diseases
mi
from
New York, NY
Atorvastatin to Prevent Avascular Necrosis of Bone in Steroid Treated Exacerbated Systemic Lupus Erythematosus
AVN Prevention With Lipitor in Lupus Erythematosus APLLE Trial
Status: Enrolling
Updated: 12/31/1969
New York University, The Hospital for Joint Diseases
mi
from
New York, NY
Click here to add this to my saved trials
Preventive IVIG Therapy for Congenital Heart Block
Preventive IVIG Therapy for Congenital Heart Block (The PITCH Study)
Status: Enrolling
Updated:  12/31/1969
Saint Barnabas Medical Center
mi
from
Livingston, NJ
Preventive IVIG Therapy for Congenital Heart Block
Preventive IVIG Therapy for Congenital Heart Block (The PITCH Study)
Status: Enrolling
Updated: 12/31/1969
Saint Barnabas Medical Center
mi
from
Livingston, NJ
Click here to add this to my saved trials
Preventive IVIG Therapy for Congenital Heart Block
Preventive IVIG Therapy for Congenital Heart Block (The PITCH Study)
Status: Enrolling
Updated:  12/31/1969
New York University School of Medicine / NYU-Hospital for Joint Diseases
mi
from
New York, NY
Preventive IVIG Therapy for Congenital Heart Block
Preventive IVIG Therapy for Congenital Heart Block (The PITCH Study)
Status: Enrolling
Updated: 12/31/1969
New York University School of Medicine / NYU-Hospital for Joint Diseases
mi
from
New York, NY
Click here to add this to my saved trials
Expression of Fas Protein in Skin Biopsies of Participants With Scarring Alopecia
Expression of Fas Protein in Skin Biopsies of Participants With Scarring Alopecia
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Health Sciences, Dermatology
mi
from
Winston-Salem, NC
Expression of Fas Protein in Skin Biopsies of Participants With Scarring Alopecia
Expression of Fas Protein in Skin Biopsies of Participants With Scarring Alopecia
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Health Sciences, Dermatology
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Birmingham, AL
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Little Rock, AR
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Hemet, CA
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Hemet, CA
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Huntington Beach, CA
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Huntington Beach, CA
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
La Jolla, CA
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Los Angeles, CA
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
San Leandro, CA
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Leandro, CA
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Thousand Oaks, CA
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Thousand Oaks, CA
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Torrance, CA
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Torrance, CA
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Aurora, CO
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Colorado Springs, CO
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Denver, CO
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Bridgeport, CT
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Bridgeport, CT
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Farmington, CT
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Farmington, CT
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Aventura, FL
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Aventura, FL
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Brandon, FL
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Brandon, FL
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Clearwater, FL
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Clearwater, FL
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Debary, FL
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Debary, FL
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Fort Lauderdale, FL
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Jupiter, FL
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Jupiter, FL
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Ormond Beach, FL
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Ormond Beach, FL
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Palm Harbor, FL
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Palm Harbor, FL
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Plantation, FL
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Plantation, FL
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Port Orange, FL
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Port Orange, FL
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Tampa, FL
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Vero Beach, FL
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Vero Beach, FL
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Atlanta, GA
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Duluth, GA
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Duluth, GA
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Idaho Falls, ID
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Idaho Falls, ID
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Chicago, IL
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Indianapolis, IN
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Shreveport, LA
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Shreveport, LA
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Lansing, MI
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Lansing, MI
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Florissant, MO
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Florissant, MO
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Nashua, NH
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Nashua, NH
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Freehold, NJ
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Freehold, NJ
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Trenton, NJ
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Trenton, NJ
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Las Cruces, NM
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Las Cruces, NM
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Brooklyn, NY
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Great Neck, NY
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Great Neck, NY
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Manhasset, NY
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Manhasset, NY
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
New York, NY
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Roslyn, NY
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Roslyn, NY
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Charlotte, NC
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Charlotte, NC
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Durham, NC
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Durham, NC
Click here to add this to my saved trials
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Wilmington, NC
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Wilmington, NC
Click here to add this to my saved trials